Donor bone marrow together with recipient regulatory T cells induces chimerism without irradiation in kidney transplantation
Authors:
- Thomas WekerleTWThomas Wekerle
- Moritz MuckenhuberMMMoritz Muckenhuber
- Andreas HeinzelAHAndreas Heinzel
- Ana F. DavidADAna F. David
- Verena KainzVKVerena Kainz
- Karin HuKHKarin Hu
- Konstantinos MengrelisKMKonstantinos Mengrelis
- Roman Reindl-SchwaighoferRRRoman Reindl-Schwaighofer
- Bruno WatschingerBWBruno Watschinger
- 17 June 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (854) , eaee6850
Abstract
Cotransplantation of donor bone marrow (BM) has yielded a therapeutic benefit in clinical trials of kidney transplantation by inducing chimerism-based tolerance, but this was dependent on unfavorable recipient irradiation. Additional regulatory T (T reg ) cell administration can overcome the need for myelosuppression, but this has been demonstrated only in mice so far. Here, we conducted a controlled, phase 1/2a trial of combined BM and T reg cell therapy in HLA-mismatched living-donor kidney transplantation (NCT03867617). Six patients received polyclonal recipient T reg cells and donor BM cells (BMCs) immediately posttransplant. Immunosuppression consisted of thymoglobulin, belatacept, sirolimus, steroids, and short-course tocilizumab. The control group received no T reg cells, BMCs, or tocilizumab. Total leukocyte donor chimerism was detected across all patients in the study group posttransplantation. This was not observed in any patient belonging to the control group, consequently meeting the primary end point of higher chimerism levels in the study versus control groups ( P = 0.001). Chimerism was observed across multiple lineages, with up to 4% in T cells. For three patients in the study group, immunosuppression could be minimized to belatacept monotherapy. Antidonor reactivity was decreased in in vitro T cell proliferation assays, suggesting specific downmodulation of the antidonor T cell response. In addition, expansion of antidonor T cell clones was shown by T cell receptor sequencing analysis to be dampened in the study versus control groups. This trial serves as a proof of concept for a combination cell therapy that induces chimerism-based immunomodulation in kidney transplantation without the need for irradiation.Keywords
Funding Information
- Vienna Science and Technology Fund (LS18-031)
This publication has 41 references indexed in Scilit:
- Induction of immune tolerance in living related human leukocyte antigen–matched kidney transplantation: A phase 3 randomized clinical trialAmerican Journal of Transplantation, 2025
- Combination cell therapy leads to clonal deletion of donor-specific T cells in kidney transplant recipientsEBioMedicine, 2024
- Optimum timing of antithymocyte globulin in relation to adoptive regulatory T cell therapyAmerican Journal of Transplantation, 2023
- Detection and Monitoring of Lineage-Specific Chimerism by Digital Droplet PCR-Based Testing of Deletion/Insertion PolymorphismsTransplantation and Cellular Therapy, 2020
- Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trialsThe Lancet, 2020
- Strategies for long-term preservation of kidney graft functionThe Lancet, 2017
- Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trialThe Lancet Oncology, 2014
- T-regulatory cell treatment prevents chronic rejection of heart allografts in a murine mixed chimerism modelThe Journal of Heart and Lung Transplantation, 2013
- Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytesNature Medicine, 2007
- Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatmentNature Medicine, 2000